Acurx Pharmaceuticals announced that ibezapolstat preserves beneficial gut microbes in multiply-recurrent C. difficile infection and outperforms standard antibiotics in biofilm killing. A pilot trial in rCDI is set to begin, with plans for FDA approval under the Limited Population Pathway if successful.
The University of Houston and DHR Health broke ground on a 64,000-square-foot medical research and education center in McAllen. Backed by a $15 million state appropriation, the project will expand physician training, research and health education in the Rio Grande Valley.
Acurx Pharmaceuticals announced a new clinical trial program for ibezapolstat in patients with recurrent C. difficile infection, building on Phase 2 results showing 96% clinical cure rates with no recurrence while sparing the gut microbiome.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07579182 |
Hormones, Outcomes, and Pain Pathways in Exercise Study |
RECRUITING | PHASE1 |
| NCT07531264 |
Neuro-Intermuscular Coordination Enhancement (NICE) Rehabilitation Through Human-Machine Interaction in Chronic Stroke |
NOT_YET_RECRUITING | EARLY_PHASE1 |
| NCT07227220 |
Summer Youth Employment Programs for Health Promotion |
COMPLETED | EARLY_PHASE1 |
| NCT07024992 |
Enhancing Smoking Cessation for African American People Everywhere |
RECRUITING | PHASE2 |
| NCT07007195 |
Smart Olfaction App to Reduce Relapse |
RECRUITING | EARLY_PHASE1 |
| NCT06774300 |
Evaluating Telehealth Delivery of Brief Alcohol Screening and Intervention for College Students |
RECRUITING | NA |
| NCT05881759 |
Integrating Food Rx With Best Feeding Practices With EFNEP |
RECRUITING | NA |
| NCT05709002 |
Smoking, Stress, HIV and Mobile Technology |
COMPLETED | NA |
| NCT05537220 |
Oral N-acetylcysteine for Retinitis Pigmentosa |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT05490927 |
Ethnic Microaggressions and Smoking Behaviors Among Latinx Adults |
COMPLETED | NA |
